Regeneron Pharmaceuticals Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2008 | $-89.1M | $-123.9M | $34.9M | — |
| FY2009 | $-69.9M | $-167.3M | $97.3M | $31.3M |
| FY2010 | $99.2M | $-467.0K | $99.7M | $39.9M |
| FY2011 | $-141.7M | $-198.9M | $57.2M | $56.1M |
| FY2012 | $-74.6M | $-124.0M | $49.3M | $94.2M |
| FY2013 | $588.6M | $432.3M | $156.3M | $215.4M |
| FY2014 | $752.4M | $419.4M | $333.0M | $321.8M |
| FY2015 | $1.33B | $652.8M | $677.9M | $459.0M |
| FY2016 | $1.49B | $974.0M | $511.9M | $559.9M |
| FY2017 | $1.31B | $1.03B | $272.6M | $507.3M |
| FY2018 | $2.20B | $1.81B | $383.1M | $427.4M |
| FY2019 | $2.43B | $2.00B | $429.6M | $464.3M |
| FY2020 | $2.62B | $2.00B | $614.6M | $432.0M |
| FY2021 | $7.08B | $6.53B | $551.9M | $601.7M |
| FY2022 | $5.01B | $4.42B | $590.1M | $725.0M |
| FY2023 | $4.59B | $3.88B | $718.6M | $885.0M |
| FY2024 | $4.42B | $3.66B | $755.9M | $982.8M |
| FY2025 | $4.98B | $4.08B | $898.4M | $993.7M |